Abstract:Adolescents exhibit remarkable heterogeneity in the structural architecture of brain development. However, due to the lack of large-scale longitudinal neuroimaging studies, existing research has largely focused on population averages and the neurobiological basis underlying individual heterogeneity remains poorly understood. Using structural magnetic resonance imaging from the IMAGEN cohort (n=1,543), we show that adolescents can be clustered into three groups defined by distinct developmental patterns of whole-brain gray matter volume (GMV). Genetic and epigenetic determinants of group clustering and long-term impacts of neurodevelopment in mid-to-late adulthood were investigated using data from the ABCD, IMAGEN and UK Biobank cohorts. Group 1, characterized by continuously decreasing GMV, showed generally the best neurocognitive performances during adolescence. Compared to Group 1, Group 2 exhibited a slower rate of GMV decrease and worsened neurocognitive development, which was associated with epigenetic changes and greater environmental burden. Further, Group 3 showed increasing GMV and delayed neurocognitive development during adolescence due to a genetic variation, while these disadvantages were attenuated in mid-to-late adulthood. In summary, our study revealed novel clusters of adolescent structural neurodevelopment and suggested that genetically-predicted delayed neurodevelopment has limited long-term effects on mental well-being and socio-economic outcomes later in life. Our results could inform future research on policy interventions aimed at reducing the financial and emotional burden of mental illness. ### Competing Interest Statement Dr Banaschewski served in an advisory or consultancy role for Lundbeck, Medice, Neurim Pharmaceuticals, Oberberg GmbH, Shire. He received conference support or speaker's fee by Lilly, Medice, Novartis and Shire. He has been involved in clinical trials conducted by Shire & Viforpharma. He received royalties from Hogrefe, Kohlhammer, CIP Medien, Oxford University Press. The present work is unrelated to the above grants and relationships. Dr Barker receives honoraria for teaching from GE Healthcare. Dr Poustka served in an advisory or consultancy role for Roche and Viforpharm and received speaker's fee by Shire. She received royalties from Hogrefe, Kohlhammer and Schattauer. The present work is unrelated to the above grants and relationships. The other authors report no biomedical financial interests or potential conflicts of interest. ### Funding Statement This work received support from the following sources: National Key R&D Program of China (No.2019YFA0709502), National Key R&D Program of China (No.2018YFC1312904), Shanghai Municipal Science and Technology Major Project (No.2018SHZDZX01), ZJ Lab, and Shanghai Center for Brain Science and Brain-Inspired Technology, the 111 Project (No.B18015), the European Union-funded FP6 Integrated Project IMAGEN (Reinforcement-related behaviour in normal brain function and psychopathology) (LSHM-CT-2007-037286), the Horizon 2020 funded ERC Advanced Grant 'STRATIFY' (Brain network based stratification of reinforcement-related disorders) (695313), Human Brain Project (HBP SGA 2, 785907, and HBP SGA 3, 945539), the Medical Research Council Grant 'c-VEDA' (Consortium on Vulnerability to Externalizing Disorders and Addictions) (MR/N000390/1), the National Institute of Health (NIH) (R01DA049238, A decentralized macro and micro gene-by-environment interaction analysis of substance use behavior and its brain biomarkers), the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London, the Bundesministeriumfur Bildung und Forschung (BMBF grants 01GS08152; 01EV0711; Forschungsnetz AERIAL 01EE1406A, 01EE1406B; Forschungsnetz IMAC-Mind 01GL1745B), the Deutsche Forschungsgemeinschaft (DFG grants SM 80/7-2, SFB 940, TRR 265, NE 1383/14-1), the Medical Research Foundation and Medical Research Council (grants MR/R00465X/1 and MR/S020306/1), the National Institutes of Health (NIH) funded ENIGMA (grants 5U54EB020403-05 and 1R56AG058854-01), NSFC grant 82150710554 and environMENTAL grant. Further support was provided by grants from: - the ANR (ANR-12-SAMA-0004, AAPG2019 - GeBra), the Eranet Neuron (AF12-NEUR0008-01 - WM2NA; and ANR-18-NEUR00002-01 - ADORe), the Fondation de France (00081242), the Fondation pour la Recherche Medicale (DPA20140629802), the Mission Interministerielle de Lutte-contre-les-Drogues-et-les-Conduites-Addictives (MILDECA), the Assistance-Publique-Hopitaux-de-Paris and INSERM (interface grant), Paris Sud University IDEX 2012, the Fondation de l'Avenir (grant AP-RM-17-013), the Federation pour la Recherche sur le Cerveau; the National Institutes of Health, Science Foundation Ireland (16/ERCD/3797), U.S.A. (Axon, Testosterone and Mental Health during Adolescence; RO1 MH085772-01A1) and by NIH Consortium grant U54 EB020403, supported by a cross-NIH alliance that funds Big Data to Knowledge Centres of Excellence. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Data from the ABCD study are available from a dedicated database: https://abcdstudy.org/ by applicaton; data from the IMAGEN study are available upon application: https://imagen2.cea.fr; HCP data are available from: https://www.humanconnectome.org/ by applicaton; PNC data are available from dbGaP: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000607.v3.p2 by application; and UKB data are available from https://biobank.ndph.ox.ac.uk/ by application ID 19542. Summary statistics from published GWAS of ADHD, ASD, EA and IQ are available at https://atlas.ctglab.nl/. Summary statistics of the GWAS for delayed brain development in this study will be uploaded to https://atlas.ctglab.nl/ upon publication. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data from the ABCD study are available from a dedicated database: by applicaton; data from the IMAGEN study are available upon application: ; HCP data are available from: by applicaton; PNC data are available from dbGaP: by application; and UKB data are available from by application ID 19542. Summary statistics from published GWAS of ADHD, ASD, EA and IQ are available at . Summary statistics of the GWAS for delayed brain development in this study will be uploaded to upon publication.

Immune-Related Genetic Overlap Between Regional Gray Matter Reductions and Psychiatric Symptoms in Adolescents, and Gene-Set Validation in a Translational Model

Genetic-Dependent Brain Signatures of Resilience: Interactions among Childhood Abuse, Genetic Risks and Brain Function

A shared neural basis underlying psychiatric comorbidity

Unravelling Robust Brain-Behavior Links of Depressive Symptoms Through Granular Network Models: Understanding Heterogeneity and Clinical Implications

The IMAGEN Study: Reinforcement-Related Behaviour in Normal Brain Function and Psychopathology

Association of a Schizophrenia-Risk Nonsynonymous Variant With Putamen Volume in Adolescents: A Voxelwise and Genome-Wide Association Study

Genome-wide association meta-analysis of childhood and adolescent internalising symptoms

Genome-Wide Analysis Of Adolescent Psychotic-Like Experiences Shows Genetic Overlap With Psychiatric Disorders

EARLY LIFE ADVERSITY AND SOCIAL WITHDRAWAL BEHAVIOR – IDENTIFYING RISK FOR ADULT PSYCHOPATHOLOGY USING A TRANSLATIONAL MODEL AND EXPRESSION-BASED POLYGENIC SCORES.

Examining the Genetic Links between Clusters of Immune-mediated Diseases and Psychiatric Disorders

Genome‐wide Mediation Analysis of Psychiatric and Cognitive Traits Through Imaging Phenotypes

2177 – Neuroanatomical Changes Associated with Subthreshold Depression in Adolescents

Identification of structural brain alterations in adolescents with depressive symptomatology

Inflammation and immune system pathways as biological signatures of adolescent depression—the IDEA-RiSCo study

Unravelling robust brain-behavior links of depressive complaints through granular network models for understanding heterogeneity

Genome-wide Association Meta-analysis of Childhood and Adolescent Internalizing Symptoms

Role of Inflammation in Depressive and Anxiety Disorders, Affect, and Cognition: Genetic and Non-Genetic Findings in the Lifelines Cohort Study

Mapping common grey matter volume deviation across child and adolescent psychiatric disorders

Structural Neurodevelopment at the Individual Level - a Life-Course Investigation Using ABCD, IMAGEN and UK Biobank Data

Identification of Common Variants Associated with Human Hippocampal and Intracranial Volumes.

Methylation pattern and mRNA expression of synapse-relevant genes in the MAM model of schizophrenia in the time-course of adolescence